Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)


Options:
A: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 150 µg, Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
C: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: F 4.5 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 4.5mg | Arm Label: F 9.0 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 9 mg | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Turbuhaler® placebo | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 4.5mg; Assigned to Arm(s): F 4.5 bid | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 9 mg; Assigned to Arm(s): F 9.0 bid | Intervention Type: DRUG; Name: Turbuhaler® placebo; Assigned to Arm(s): PBO

Answer: C